Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Published Online: 2023-10-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Andrew J Armstrong•Cagatay Arslan•Christian Poehlein•Emma Brown•Francis Parnis•Fred Saad•Friederike Schlürmann•Giuseppe Procopio•Jae Young Joung•João Daniel Guedes•Laura Barker•Mikio Sugimoto•Mototsugu Oya•Neal Shore•Niven Mehra•Noel W Clarke•Oliver Sartor•Paula Michelle del Rosario•Yu-Zhen Liu
